We are live on
!
Find out more
Boston Trust Walden Portfolio holdings
AUM
$13.1B
Turnover
6.42%
1-Year Est. Return
24.63%
This Fund
S&P 500
This Quarter
Est. Return
+2.88%
1 Year Est. Return
+24.63%
3 Year Est. Return
+61.41%
5 Year Est. Return
+82.17%
10 Year Est. Return
+348.29%
AUM
$6.88B
AUM Growth
+$149M
(+2.2%)
Cap. Flow
-$5.76M
Cap. Flow
% of AUM
-0.08%
Top 10 Holdings %
Top 10 Hldgs %
10.94%
Holding
341
New
18
Increased
129
Reduced
136
Closed
6
Avg Time Held
0.9
years
Top 10 Avg Time Held
0.7
years
Top 20 Avg Time Held
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ubiquiti
UI
|
+$38.9M |
| 2 |
ESRX
Express Scripts Holding Company
ESRX
|
+$19.5M |
| 3 |
Unifirst Corp
UNF
|
+$9.4M |
| 4 |
PPG Industries
PPG
|
+$8.9M |
| 5 |
Centene
CNC
|
+$8.89M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Liquidity Services
LQDT
|
+$29.4M |
| 2 |
RPC Inc
RES
|
+$20.1M |
| 3 |
Coherent
COHR
|
+$20.1M |
| 4 |
Virtus Investment Partners
VRTS
|
+$19.5M |
| 5 |
AGN
Allergan Inc
AGN
|
+$16.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.96% |
| 2 | Technology | 15.98% |
| 3 | Industrials | 15.5% |
| 4 | Healthcare | 12.25% |
| 5 | Consumer Discretionary | 11.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
326
Regeneron Pharmaceuticals
REGN
$81.4B
| $282K | ﹤0.01% |
1,000
| – | – |
2013 Q2
4 quarters
|
|
327
McKesson
MCK
$117B
| $280K | ﹤0.01% |
1,501
| – | – |
2013 Q3
3 quarters
|
|
328
DELISTED
Unilever NV New York Registry Shares
UN
| $274K | ﹤0.01% |
6,265
| – | – |
2013 Q2
4 quarters
|
|
329
NextEra Energy
NEE
$166B
| $246K | ﹤0.01% |
9,600
| – | – |
2013 Q2
4 quarters
|
|
330
Cabot Corp
CBT
$3.84B
| $243K | ﹤0.01% |
4,198
-1,085
| -21% | -$63.2K |
2013 Q4
2 quarters
|
|
331
Henry Schein
HSIC
$9.63B
| $234K | ﹤0.01% |
5,036
-1,339
| -21% | -$61.3K |
2013 Q2
4 quarters
|
|
332
DELISTED
JP Morgan Alerian MLP Index ETN 5/24/24
AMJ
| $221K | ﹤0.01% |
+4,210
| New | +$207K |
2014 Q2
0 quarters
|
|
333
Mastercard
MA
$541B
| $220K | ﹤0.01% |
3,000
| – | – |
2013 Q3
3 quarters
|
|
334
Enterprise Products Partners
EPD
$79.5B
| $216K | ﹤0.01% |
+5,518
| New | +$204K |
2014 Q2
0 quarters
|
|
335
AstraZeneca
AZN
$257B
| $201K | ﹤0.01% |
+2,700
| New | +$195K |
2014 Q2
0 quarters
|
|
|
336
Coherent
COHR
$45.9B
| – | – |
-1,302,947
| Closed | -$20.1M | – |
|
|
337
Liquidity Services
LQDT
$1.37B
| – | – |
-1,129,188
| Closed | -$29.4M | – |
|
338
Neogen
NEOG
$2.58B
| – | – |
-819,816
| Closed | -$13.8M | – |
|
|
ASEI
339
DELISTED
AMER SCIENCE & ENGR INC.
ASEI
| – | – |
-203,099
| Closed | -$13.6M | – |
|
Similar funds
Boston Trust Walden's Q2 2014 Portfolio in Review
As of Q2 2014, Boston Trust Walden held 341 positions worth $6.88B, up 2.2% from $6.73B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Boston Trust Walden's Q2 2014 filing shows 18 new, 129 increased, 136 reduced and 6 closed positions. Its largest new stake was Ubiquiti: 989,903 shares worth $44.7M. The largest sale was Liquidity Services, an estimated $29.4M.
By sector, the portfolio is most concentrated in Financials at 17% of assets, down from 18% a quarter earlier, followed by Technology and Industrials.
- Boston Trust Walden's largest Q2 2014 buy was Ubiquiti: 989,903 shares worth $44.7M.
- Boston Trust Walden added most to Express Scripts Holding Company in Q2 2014, an estimated $19.5M increase.
- Boston Trust Walden's biggest Q2 2014 reduction was RPC Inc, cutting an estimated $20.1M.
- Boston Trust Walden fully exited Liquidity Services in Q2 2014, selling an estimated $29.4M.
- Boston Trust Walden's ten largest holdings make up 11% of its $6.88B portfolio in Q2 2014.
- Boston Trust Walden opened 18 new positions and closed 6 in Q2 2014.
- Boston Trust Walden's portfolio value rose 2.2% quarter-over-quarter to $6.88B.
Based on Boston Trust Walden's 13F filing for Q2 2014, filed 1 Aug 2014.